Inventor · disambiguated record
Michael Kulke
Also filed as: KULKE MICHAEL
10 granted patents·6 pending applications·8 citations·filing 2006–2024
82Inventor score
Top patents by PatentIndex Score
16 records- 0180US11583569B2PSMA-targeting amanitin conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2018·Granted Feb 21, 2023·2 cites·18 claims
- 0275US11420971B2Method for synthesizing amanitinsHEIDELBERG PHARMA RES GMBH·Filed 2018·Granted Aug 23, 2022·1 cites·8 claims
- 0375US10961277B2Method for synthesizing amanitinsHEIDELBERG PHARMA RES GMBH·Filed 2018·Granted Mar 30, 2021·1 cites·9 claims
- 0475US2025064960A1B-lymphocyte specific amatoxin antibody conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2024·Application pending·0 cites
- 0574US12201693B2Amanitin conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2023·Granted Jan 21, 2025·0 cites·5 claims
- 0673US11590238B2Amanitin conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2017·Granted Feb 28, 2023·1 cites·6 claims
- 0772US2025009901A1Composition comprising a combination of immune checkpoint inhibitor and antibody-amatoxin conjugate for use in cancer therapyHEIDELBERG PHARMA RES GMBH·Filed 2024·Application pending·0 cites
- 0871US12403201B2B-lymphocyte specific amatoxin antibody conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2022·Granted Sep 2, 2025·0 cites·8 claims
- 0970US11926631B2Method of treating cancer using amanitin derivativesHEIDELBERG PHARMA RES GMBH·Filed 2022·Granted Mar 12, 2024·0 cites·4 claims
- 1070US7378401B2Use of Fosfluridine Tidoxil (FT) for the treatment of intraepithelial proliferative diseasesHEIDELBERG PHARMA GMBH·Filed 2006·Granted May 27, 2008·2 cites·13 claims
- 1168US11446388B2Amanitin antibody conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2017·Granted Sep 20, 2022·1 cites·3 claims
- 1264US11702451B2Method for synthesizing amanitinsHEIDELBERG PHARMA RES GMBH·Filed 2021·Granted Jul 18, 2023·0 cites·20 claims
- 1363US2024307549A1Subcutaneously administered antibody-drug conjugates for use in cancer treatmentHEIDELBERG PHARMA RES GMBH·Filed 2024·Application pending·0 cites
- 1461US2022133902A1Composition Comprising a Combination of Immune Checkpoint Inhibitor and Antibody-Amatoxin Conjugate for Use in Cancer TherapyHEIDELBERG PHARMA RES GMBH·Filed 2021·Application pending·0 cites
- 1560US2023355792A1Methods of improving the therapeutic indexHEIDELBERG PHARMA RES GMBH·Filed 2023·Application pending·0 cites
- 1648US2025195678A1B-lymphocyte specific amatoxin antibody conjugatesHEIDELBERG PHARMA RES GMBH·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Michael Kulke files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →